Results 161 to 170 of about 18,762 (211)

Risk assessment of asthma and allergic rhinitis in atopic dermatitis patients treated with biologics and JAK inhibitors: a systematic review and network meta-analysis of randomized controlled trials. [PDF]

BMC Med
Zeng L, Zhou T, Zhang L, Xian M, Zhu Z, Liu J, Fu S, Luo H, Li J.   +8 more
europepmc   +1 more source

Comparison of long-term efficacy, tolerability and drug survival rates of baricitinib as monotherapy or combination therapy in RA patients: data from a real-world prospective cohort study. [PDF]

RMD Open
Temiz A, Tascilar K, Kleyer A, Hueber AJ, Hartmann F, Schett G, Bayat S.   +6 more
europepmc   +1 more source

Differential risk of adverse drug reactions with baricitinib across age groups: integrating real-world pharmacovigilance and genetic causal inference. [PDF]

Ther Adv Drug Saf
Zeng H, Liu W, Li A, Liu H, Li X, Lai J, Chen M, Xiong G, Zhang Y.   +8 more
europepmc   +1 more source

Severe Hepatic Adverse Event Induced by Anti-HER2 Therapy in Breast Cancer: A Case of Successful Immunotherapy With Baricitinib. [PDF]

ACR Open Rheumatol
Li Y, Wang Y, Shao M, He J.
europepmc   +1 more source

Janus Kinase Inhibitors for Treatment of Palmoplantar Pustulosis, Generalized Pustular Psoriasis, and Palmoplantar Pustular Psoriasis: A Systematic Review of the Literature. [PDF]

Health Sci Rep
Ansari MS, Heidari S, Pourgholi E, Bahramian S, Tootoonchi N, Vahabi SM.   +5 more
europepmc   +1 more source

Mastering the Use of Systemic JAK Inhibitors for Atopic Dermatitis: A Dermatologist's Practical Guide. [PDF]

Am J Clin Dermatol
Jalili A, Labbouz S, Gooderham M, Ziv M, Dodiuk-Gad RP.   +4 more
europepmc   +1 more source

Revisiting Janus kinases as molecular drug targets for rheumatic diseases. [PDF]

Front Med (Lausanne)
Kwon S.
europepmc   +1 more source

Towards New Strategies: Case Report and Review of the Literature-Effective Use of JAK Inhibitor Baricitinib in a 4-Year-Old Boy with Anti-MDA5 Antibody-Positive Juvenile Dermatomyositis. [PDF]

J Clin Med
Buzoianu O, Satirer Ö, Kuemmerle-Deschner JB, Reiser C.   +3 more
europepmc   +1 more source

Baricitinib triggering a central nervous system inflammatory-demyelinating disease: A case report. [PDF]

Mult Scler J Exp Transl Clin
Khalili R, Toubasi AA, Poursheykhi M, Bagnato F.   +3 more
europepmc   +1 more source

Oral JΑΚ Inhibitors in Vitiligo Treatment. [PDF]

Dermatol Ther (Heidelb)
Panagopoulou A, Sotiriou E, Papadimitriou I, Pavlidis A, Bakirtzi K, Tsentemeidou A, Arabatzis M, Vakirlis E, Kiritsi D.   +8 more
europepmc   +1 more source